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SUMMARY 
Amyotrophic lateral sclerosis is one of the major neurodegenerative diseases, causing an 
ascending paralysis that usually kills the patient within a few years from disease onset. The 
motor neurons show aggregates of proteins which in approximately 20 % of cases of the 
familial form contain mutated SOD1 protein.  
Trehalose is a disaccharide which has been shown to reduce protein aggregation and increase 
viability in cell models and alleviate symptoms in animal models of several 
neurodegenerative diseases associated with protein aggregation. When given orally to the 
SOD1
G93A 
mouse model of ALS, trehalose failed to slow down the disease progression, which 
has led to questions about the uptake and distribution of the molecule in this mouse strain. 
The aim of this study was to investigate whether significant levels of trehalose reach the 
central nervous system of the SOD1
G93A
 mouse after oral administration. This was performed 
by a trehalose assay of the brain of trehalose treated animals. A glucose assay was optimised 
for use in small samples of brain lysate after the digestion of trehalose into glucose by 
trehalase, and the difference in glucose concentration before and after digestion represented 
the trehalose level. No significant differences were detected between digested and undigested 
samples in trehalose treated mice (46.58±10.39 µg/g wet tissue and 41.86±7.93 µg/g, 
respectively) or in control mice (60.94±11.39 µg/g wet tissue and 71.58±10.25 µg/g, 
respectively). 
Additionally, the possible effects of trehalose were assessed by histological evaluation of 
spinal cord sections stained with an antibody directed towards misfolded SOD1 protein. A 
semi-quantitative method was used to evaluate the number of neurons in different categories 
of staining and significant differences were only found in the extracellular staining of female 
mouse spinal cord, where trehalose treated animals showed more intense extracellular staining 
(p=0.031). Since the study used small groups of animals (n = 4-5 mice), it is possible that the 
significant result is a false positive, which would support the overall conclusion that trehalose 
does not reach the central nervous system of the SOD1
G93A
 mouse in significant amounts. 
  
SAMMANFATTNING 
Amyotrofisk lateralskleros (ALS) är en av de vanligaste neurodegenerativa sjukdomarna hos 
människor och påverkar övre och nedre motorneuron. Det är en sent insättande progressiv 
sjukom som oftast yttrar sig initialt genom asymmetrisk muskelsvaghet i ben eller armar eller 
sluddrande tal och utvecklas till en successivt mer utbredd förlamning. Andningsdepression är 
den vanligaste dödsorsaken hos ALS-patienter och sker oftast inom 2-5 år efter 
symptomdebut. 
Fem till tio procent av ALS-patienter har en släkting med sjukdomen, varför begreppet 
familjär ALS (fALS) har myntats för denna grupp. Hos 20 % av fALS-patienter är SOD1-
genen muterad, men funktionen av detta är oklar. Dock har man sett att modifierade SOD1-
protein bildar intracellulära plack, vilka tycks påverka sjukdomsutvecklingen. Transgena 
musmodeller av ALS har utvecklats genom att inkorporera en muterad variant av  
SOD1-genen. 
Syftet med den redovisade studien var att undersöka huruvida oralt intagen trehalos når 
centrala nervsystemet hos musmodellen SOD1
G93A
. Bakgrunden till detta är att flera studier 
av trehalos visat lovande resultat i form av minskad  proteinaggregering och ökad överlevnad 
hos cell- och djurmodeller av flera neurodegenerativa sjukdomar. En tidigare studie utförd på 
SOD1-möss visade dock inga skillnader på symptomutveckling eller överlevnad vid oralt 
intag av trehalos. Detta har väckt frågor angående upptag och distribution av trehalos hos 
dessa möss. 
Vår frågeställning var huruvida trehalos tas upp från tarmen till centrala nervsystemet, vilket 
undersöktes genom en mätning av trehaloskoncentrationen i hjärnvävnad från oralt 
trehalosbehandlade möss. En kommersiell mätmetod för glukoskoncentration optimerades för 
analys av små volymer av hjärnlysat före och efter digerering av trehalos till glukos. 
Skillnaden i glukoskoncentration före och efter digerering representerade trehalos-
koncentrationen. Inga signifikanta skillnader noterades mellan digererade och odigererade 
prover hos trehalosbehandlade möss (46,58±10,39 respektive 41,86±7,93 μg/g vävnad) eller 
kontrolldjur (60,94±11,39 respektive 71,58±10,25 μg/g vävnad). 
Dessutom studerades eventuella effekter av trehalos genom en immunohistologisk utvärdering 
av ryggmärgssnitt infärgade med en antikropp riktad mot muterat SOD1-protein. En 
semikvantitativ metod användes för att utvärdera antalet neuron i olika kategorier av färgning. 
Signifikanta skillnader mellan trehalosbehandlade och kontrolldjur observerades endast i 
kategorin extracellulär färgning hos honor, där trehalosbehandlade honors ryggmärg färgades 
mer intensivt extracellulärt (p=0,031). Då studien var av liten storlek (n = 4-5 möss) är det 
möjligt att detta enda signifikanta resultat är falskt positivt, vilket skulle stämma överens med 
den övergripande slutsatsen som indikerar att trehalos vid oral administration inte når CNS 
hos SOD1
G93A
-möss i signifikanta mängder.  
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ABBREVIATIONS 
ALS = amyotrophic lateral sclerosis 
CNS = central nervous system 
fALS = familial amyotrophic lateral sclerosis 
FUS/TLS = fused in sarcoma/translocated in liposarcoma  
LC3 = microtubule-associated protein 1 light chain 3 
OPMD = oculopharyngeal muscular dystrophy 
PCR = polymerase chain reaction 
sALS = sporadic amyotrophic lateral sclerosis 
SOD1 = Cu/Zn superoxide dismutase 1 
TDP-43 = TAR DNA-binding protein of 43 kDa 
VAPB = vesicle-associated membrane protein B 
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INTRODUCTION AND LITERATURE REVIEW 
Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease selectively 
affecting upper and lower motor neurons. The degeneration of lower motor neurons seems to 
be ascending from the neuromuscular junctions or axons, ending with the disintegration of the 
entire neuron. It is a late-onset disease that most often causes asymmetric muscle weakness of 
the limbs (cervical or lumbar onset) or slurring of speech (bulbar onset) as a first symptom. 
The progression continues to paralysis and death, usually from respiratory failure, with a 
median age of survival of three to five years for patients with cervical or lumbar onset and 
two to three years after bulbar onset (Wijesekera & Leigh. 2009). ALS occurs worldwide and 
has a European incidence of about 2 per 100 000 person-years, which makes it one of the 
major neurodegenerative diseases (Logroscino et al., 2010). 
There have been many theories as to what causes ALS, including heavy metal exposure and 
viral infections, but while no external factors have been convincingly attributed to the 
pathogenesis, 5-10% of patients have a familial history of ALS (Rowland & Shneider, 2001). 
Since the majority of ALS patients do not have any obvious genetic link to another ALS 
patient, there is today a subdivision into familial ALS (fALS) and sporadic ALS (sALS). The 
familial form is predominantly inherited in an autosomal dominant fashion. 
SOD1 
The SOD1 gene was the first to be linked to familial ALS, and it is estimated that up to 20 % 
of fALS cases show mutations in this gene (Rosen et al., 1993). It encodes the protein Cu/Zn 
superoxide dismutase 1, a 32 kDa enzyme that has a number of functions in the cell. Probably 
most importantly, it functions as an antioxidant by catalysing the dismutation of superoxide 
into hydrogen peroxide or molecular oxygen. 
The SOD1 gene has been a major subject of ALS research for over 10 years, with primarily 
autosomal dominant inheritance and more than 150 mutations (mainly missense, but also 
deletions and insertions) causing ALS-like pathology (Siddique & Ajroud-Driss, 2011).  
Different mutations of the SOD1 gene seem to cause different disease progression and 
phenotypes (e.g. rapid progression caused by the A4V mutation). Since the discovery of 
mutated SOD1, several other genes have been implicated in familial ALS. These include 
VAPB (vesicle-associated membrane protein B), TDP-43 (TAR DNA-binding protein of 43 
kDa), FUS/TLS (fused in sarcoma/translocated in liposarcoma) and C9orf72, the last of which 
carries a mutation in about one third of European familial ALS cases (Nishimura et al., 2004; 
Sreeharan et al., 2008; Vance et al., 2009; Renton et al., 2011; DeJesus-Hernandez et al., 
2011). 
Despite the correlation between mutant SOD1 protein and ALS pathology, it is still unknown 
how the mutations cause symptoms. The leading theories involve connections between the 
aggregating properties of the mutated protein to its pathology, although it is still unknown 
how protein aggregation in itself leads to neurodegeneration. To study the effects of the 
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SOD1 mutations, at least 15 mouse models of ALS that express a mutated version of the 
human SOD1 gene have been produced (Turner & Talbot, 2008). Mouse models 
overexpressing wild-type human SOD1 and SOD1 knock-out mice also show 
neurodegenerative signs, but do not develop ALS pathology, as opposed to the SOD1 mutants 
(Turner & Talbot, 2008). 
The SOD1G93A mouse model 
In ALS-related research the most commonly used model is the SOD1
G93A
 mouse strain, in 
which the glycine residue at position 93 of the SOD1 protein has been substituted by alanine 
(Gurney et al., 1994). Recombination has divided the SOD1
G93A
 mouse strain into several 
sub-strains, with different copy numbers of the mutant transgene. The number of copies 
affects age of onset, disease progression and lifespan, with a more aggressive progression 
associated with a high copy number (Turner & Talbot, 2008). The mouse most frequently 
used has a high copy number (25 predicted copies) and is called B6SJL-TgN(SOD1-
G93A)1Gur, but will be referred to as SOD1
G93A
 from this point. It expresses the mutant 
SOD1 protein in a stable and abundant manner, and the protein has dismutase activity. 
The SOD1
G93A 
mouse model starts showing signs of hind limb weakness (e.g. hypoextension 
of the hind limbs when the mice are lifted by the base of the tail) at three to four months of 
age (Gurney et al., 1994). After four months of age the stride length decreases and paralysis 
develops (Dal Canto & Gurney, 1995). A tremor of the hind limbs when suspended in the air 
develops, and the hind limbs and toes may lock in a hyperextended position when walking 
(Gurney et al., 1994). The mice are generally dying or reach the commonly used endpoint, 
defined as not being able to right themselves within 20-30 seconds after being placed on one 
side, within five months of age (Dal Canto & Gurney, 1995; Kaneb, 2012).  
Progressive histological changes have been observed, starting with vacuolar degeneration of 
the neurons in the ventral horns (from about 70 days of age to 135 days) to atrophy of the 
ventral horn (after 120 days), where a severe loss of motor neurons is observed, along with 
filamentous inclusions in the surviving neurons (Dal Canto & Gurney, 1994; Gurney et al., 
1994). At this stage, only a small number of the remaining neurons show signs of vacuolar 
degeneration. 
Degeneration of neuromuscular junctions has been reported to start as early as 25 days of age 
(Gould et al., 2006) and a decrease in the number of spinal motor neurons by 100 days of age 
(Fischer et al., 2004).  
Trehalose 
Trehalose is a disaccharide which occurs in fungi, plants and invertebrates. It has stabilising 
properties and protects cells from heat, freezing and desiccation. Upon ingestion by mice and 
humans it is believed to be rapidly broken down by the enzyme trehalase which is localised to 
the small intestine and kidneys of most mammals (Kamiya et al., 2003). 
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In several experiments, trehalose has been shown to have positive effects on models of prion 
disease, Parkinson’s and Huntington’s diseases, and oculopharyngeal muscular dystrophy 
(OPMD), on a molecular and cellular level (Béranger et al., 2008; Rodríguez-Navarro et al., 
2010; Tanaka et al., 2004; Davies et al., 2006). It has been shown to reduce the aggregate 
formation associated with these conditions and increase cell viability (Béranger et al., 2008; 
Tanaka et al., 2004; Davies et al., 2006) and it is believed to have these effects by preventing 
the formation of, rather than dissolving the already formed aggregates (Tanaka et al., 2004; 
Béranger et al., 2008). Since the formation of SOD1-containing aggregates has been shown in 
correlation with disease progression in ALS, these studies suggest that trehalose could be 
effective in alleviating ALS symptoms (Kaneb, 2012).  
Tanaka et al. (2004) have studied the effects of trehalose on molecular, cellular and animal 
models of Huntington’s disease and have published the only investigation of trehalose levels 
in the tissue of treated animals so far. As well as showing decreased polyglutamine 
aggregation and increased cell viability in culture (mouse neuroblastoma Neuro2a cells 
expressing a truncated N-terminal huntingtin), they treated the R6/2 mouse model of 
Huntington’s disease with 2% of trehalose added to their drinking water. The trehalose 
treatment reduced weight loss, as well as the number of ubiquitin positive polyglutamine 
aggregates in the brains of the R6/2 mice at 8 and 12 weeks of age. Also, macroscopic 
neuropathology and clinical signs (motor dysfunction) were ameliorated and lifespan was 
extended after trehalose treatment. The concentration of trehalose in the brains of the animals 
was reported to be 0.11 ± 0.02 nmol/μg protein (mean ± SEM). 
In a study of OPMD, trehalose ingested via the drinking water also alleviated the 
characteristic forelimb symptoms of the mouse model A17-1 (Davies et al., 2006). 
Histologically, aggregate formation and DNA fragmentation (apoptosis) were decreased in 
the biceps of the trehalose treated animals. 
A mouse model of Parkinson’s disease (parkin-deleted/tau overexpressing) fed trehalose for 
up to 4 months exhibited alleviation of cognitive and motor signs in a number of tests, a 
reduction of neuritic plaques and astrogliosis (Rodríguez-Navarro et al., 2010). However, 
weight loss was significantly exacerbated in the treated mice. Some effects were less 
pronounced (e.g. astrogliosis) or absent (e.g. dopaminergic effects) after 4 months of 
treatment, despite showing a significant effect after 2.5 months of treatment. 
Since trehalose had positive effects on aggregation of misfolded proteins in other 
neurodegenerative diseases, and had alleviated SOD1 aggregation in a cell model (Gomes et 
al., 2010), it was believed that it might have positive effects on the SOD1
G93A 
mouse model of 
ALS. However, up to 5% trehalose in the drinking water from 35 days of age did not 
significantly affect the age of disease onset, survival, motor function or the proportion of 
motor neurons showing SOD1 aggregates (Kaneb, 2012). The failure to see a response to the 
treatment in this study has raised questions about whether the trehalose was reaching the 
central nervous system (CNS). 
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The purpose of the present study was to investigate to what extent trehalose reaches the CNS 
of the SOD1
G93A
 mouse. This was explored by measuring the trehalose levels in the brains of 
trehalose treated SOD1
G93A
 mice. Since different kinds of SOD1 inclusions had been noticed 
in the work by Kaneb (2012), a re-evaluation of existing histological material from previously 
trehalose treated SOD1
G93A
 mice formed a second part of the study.  
The hypothesis was that trehalose does not reach the CNS. That would mean that no 
significant differences in trehalose concentration are to be observed between treated and 
control SOD1
G93A 
mice. Neither would any significant differences be observed between the 
two groups in the extent of aggregation of mutated SOD1 protein in the motor neurons of the 
spinal cord. 
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MATERIALS AND METHODS 
Animals 
All animals used in this study were either wildtype or hemizygous SOD1
G93A
 mice. The latter 
were bred in a colony where male mice carrying the human mutated SOD1
G93A 
gene (B6SJL-
TgN SOD1G93A 1 Gur/J, Stock number 002726, purchased from the Jackson Laboratory, 
Bar Harbour, ME) had been bred with wild-type hybrid C57Bl/6 x CBA/Ca females. The 
hemizygous SOD1
G93A 
offspring were maintained throughout more than 20 generations and 
no differences in disease progression and lifespan have been observed in the colony (Kaneb, 
2012). All animals were housed according to the Home Office code of practice and treatment 
was conducted under a Project Licence held by Professor Dominic Wells. 
Eight female SOD1
G93A
 mice were used for the definitive part of this study. After genotyping 
by polymerase chain reaction (PCR) of ear biopsy material according to previously published 
protocol (Kaneb, 2012), hemizygous female SOD1
G93A
 mice from the same litter were divided 
into a treatment group (n=4) and a control group (n=4). The mice of the treatment group were 
fed 5 % trehalose (MP Biomedicals, USA) in their drinking water from 35 to 90 days of age. 
On day 90 they were culled by spinal dislocation and their brains were collected post-mortem. 
The tissue was frozen in liquid nitrogen immediately after collection.  
Additional SOD1
G93A 
mice and wild-type mice were either not treated or treated for shorter 
periods and their tissues were used to optimise the assay. 
Trehalose assay 
Each brain was pulverised in liquid nitrogen using a pestle and mortar and suspended in 
deionised water (≥18 mΩ, 2.5 µl per mg of brain). The resulting homogenate was thoroughly 
mixed and heat treated, in aliquots of up to 500 µl, for 30 minutes in a 75°C water bath. The 
heat treated homogenates were then quickly frozen to -20°C. Once all the tissue had been 
processed, the homogenates were defrosted before being centrifuged for 20 minutes at  
13,000 g, after which the supernatant was collected. The supernatant was again centrifuged 
for 20 minutes at 13,000 g to make a clear supernatant, which was stored in a -20°C freezer. 
After defrosting, each supernatant was split into three aliquots of which one (A) was treated 
with trehalase (Megazyme International Ireland) at pH 7 and 40°C for 60 minutes. The two 
other aliquots (B and C) were diluted in the same buffer as A without trehalase and incubated 
at 40°C for 60 minutes. The glucose concentration was assessed in supernatants A and B 
using a hexokinase glucose kit (Sigma-Aldrich Co., UK) and C was used as a blank control. 
The endogenous glucose concentration of each supernatant was calculated by subtracting the 
absorbance of C, and the absorbance of the reagent, from B and convert the difference to the 
concentration of glucose in the supernatant by comparison to a glucose standard curve 
ranging from 2.5 to 80 µg/ml (0,125 to 4 µg in a volume of 50 µl). The glucose concentration 
was then calculated for the entire brain. The total glucose concentration, including that added 
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by trehalose conversion, was calculated by subtracting the absorbance of C and the reagent 
from that of A and converting it into glucose concentration in the brain in the same way. 
Samples were processed in duplicates with the sample identity hidden from the researcher, 
after which the glucose concentrations obtained were analysed using the Kruskal-Wallis one-
way analysis of variance. 
Histology 
Spinal cord sections used in a previous study (Kaneb, 2012) were histologically analysed 
using a semi-quantitative method. The tissues of trehalose treated and untreated 75-day-old 
SOD1
G93A
 mice (n=5 female and n=4 male in each group) had been sectioned and stained 
with the USOD antibody (Kerman et al., 2010) and Nissl stain as previously reported (Kaneb, 
2012). The USOD antibody (donated by Dr Avijit Chakrabartty, University of Toronto) is raised 
specifically to misfolded SOD1 protein where the hydrophobic core is exposed and the copper ion 
lost (Kerman et al., 2010). The mice had been treated with 5% trehalose in the drinking water 
from 35 days of age until they were sacrificed at 75 days of age. A scoring system for the type 
and intensity of staining was set up according to the categories suggested by Kaneb (2012). 
All sections which could not be reliably assessed were excluded from the study. Reasons for 
exclusion included folding of sections on the slide (when this resulted in interference between 
the two levels of the sections so that it was no longer clear whether USOD staining was 
directed toward motor neurons) and tearing of the tissue resulting in incomplete sections.  The 
sections had been allocated to specific levels of the spinal cord previously and this assessment 
was used to level the sections between the animals. The sections corresponding to levels 
where one or several sections could not be interpreted reliably were excluded from all the 
mice in order to get comparable results. This left seven sections that were present in all 18 
animals. 
The number of USOD positive motor neurons in each category (see below) was quantified for 
each section of every animal in a blinded fashion and the sum of positive neurons in the seven 
sections was calculated for each animal. The Kruskal-Wallis one-way analysis of variance 
was used to analyse the differences between the four groups (treated females, untreated 
females, treated males, untreated males). 
The extracellular staining was categorised (see below) for every section and the result was 
analysed using generalised estimating equations. 
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Scoring criteria for intracellular staining 
The number of neurons exhibiting the different degrees of intracellular staining was assessed 
according to the following definitions: 
- Diffuse staining: all intracellular staining which lacked a particular structure. Any 
neuron which showed intense or focal staining would be included in the other 
categories. 
- Faint inclusions: all motor neurons containing solid shapes and inclusions that seemed 
to aggregate but were less intense than “intense inclusions” below. 
- Intense inclusions: all inclusions which were intensely stained at least in some area 
(punctae to patches, one or several) up to approximately one third of the area of the 
neuron cell body 
- Intense staining throughout motor neuron: intense staining extending across more than 
one third of the area of the neuron cell body. 
Scoring criteria for extracellular staining 
The scoring of extracellular staining of individual sections was performed according to the 
following definitions: 
- None: lacking staining apart from intracellular staining (in neurons, small membrane-
bound compartments, erythrocytes or fungi), background staining or other obvious 
artefacts. 
- Mild-moderate: all staining which did not appear to be intracellular or obvious 
artefacts, but did not meet the criteria for extensive extracellular staining (see below). 
Reasons for exclusion from “extensive” could be that the staining was less intense, 
less dense, consisted of smaller punctae or covered a smaller area. 
- Extensive: staining covering at least one quarter of one ventral horn, consisting of 
intensely stained plaques larger than punctae or clearly stained vacuolar structures. 
The staining should be substantial in density throughout the assigned area. 
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RESULTS 
Trehalose assay 
Trehalase was used to convert trehalose into glucose, as the latter can be easily measured 
using an enzymatic assay. The difference between the glucose level of the untreated sample 
and that of the sample after incubation with trehalase would then be proportional to the 
original amount of trehalose (1.052 g of glucose per gram of trehalose).  
Validation of glucose assay for use in supernatant 
The glucose assay kit was validated using a 1 mg/ml glucose solution according to the 
technical bulletin. In short, this assay contains hexokinase and glucose-6-phosphate 
dehydrogenase which catalyse the conversion of glucose into 6-phosphogluconate, producing 
one NADH molecule per glucose molecule used. NADH absorbs light at 340 nm proportional 
to the original glucose concentration. Δabsorbance, defined as the absorbance of the sample 
with reagent minus the sum of the absorbance of the reagent blank (reagent and deionised 
water) and the sample blank (deionised water and sample), is used in a formula to obtain the 
actual concentration of glucose in the sample. The assay was first used in its recommended 
volumes of 1 ml reagent and 10-200 µl of sample, but when using this setup to measure the 
endogenous glucose content of supernatant from wild-type mouse brain it was concluded that 
the glucose concentration was often too low to obtain results within the recommended range. 
In order to assess the variability of the assay and to optimise the method for samples of low 
glucose concentrations, the possibility of reducing the volume was investigated.  
50 µl of sample was used with 150 µl of reagent in a 96-well ELISA UV-plate. A serial 
dilution (1:2) of glucose in deionised water, reaching a total volume of 50 µl was used in each 
experiment to obtain a standard curve, usually ranging from 5 to 80 µg/ml. Also 2.5 and 160 
µg/ml were proven to be in the linear range of the standard curve. All reactions were 
performed in duplicate.  
Since the glucose levels were lower than expected, a potential breakdown of glucose in the 
supernatant derived from a wild-type mouse brain was investigated by adding a known 
amount of glucose to one half of the supernatant while leaving the other half neat. After 
overnight incubation at 37°C, the same amount of glucose was added to the neat supernatant 
right before measuring the glucose concentration of the samples. Very similar glucose 
concentrations were obtained (results not shown), indicating that glucose is not broken down 
in the supernatant. 
The possible inhibition of the supernatant on the assay reagent was investigated using 40 µl of 
supernatant (derived from wild-type mouse brain) in different dilutions (1:1, 1:2, 1:4 and 1:8) 
and 10 µl of a glucose solution of known concentration. This experiment was first performed 
using 150 µl of reagent, which showed a small but significant decrease in glucose recovery in 
more concentrated supernatant. The experiment was repeated using 250 µl of reagent to 
explore whether the inhibitory effect was caused by too high sample:reagent ratio. This ratio 
of 50:250 is equivalent to the ratio when using the maximum sample volume recommended 
10 
 
for the assay, 200:1000. The result showed slightly higher inhibition (Figure 1), so a ratio-
dependent inhibition was ruled out. However, from this point 250 µl was used in each 
experiment in order to get as close as possible to the recommended conditions.  
 
 
 
 
 
 
 
Different amounts of glucose, similar to the standard curve, were then added to supernatant of 
dilutions 1:1, 1:2 and 1:4 in order to investigate whether the increase in glucose (representing 
the product of trehalose after trehalase digestion) could be reliably measured. The best 
correlation and correspondence to the standard curve in water was obtained in the 1:2 dilution 
of the supernatant (Figure 2). The standard curve in the 1:4 dilution of supernatant also 
corresponded well to that in water, but since it was considered important to keep the sample 
concentration as high as possible, the 1:2 dilution was chosen for further investigations. 
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Figure 1. Inhibition of the glucose assay reagent by supernatant. 
The mass of glucose recovered after adding the same amount to different 
concentrations of brain lysates (diluted with water). Mass of glucose 
recovered (m) as a function of the concentration of supernatant (c) follows the 
equations: 
m = -0.3341c + 1.3992, R
2
 = 0.9646  (250 µl) 
m = -0.2212c + 1.3587, R
2
 = 0.8758  (150 µl) 
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Validation of trehalase 
1 µl of trehalase (corresponding to 61 U at pH 7 or 148 U at pH 5.5) was chosen for digestion 
of each 50 µl sample volume, as it should contain a surplus of enzyme, and any smaller 
volume would be hard to measure accurately. 
Since the glucose standard curve worked well between 2.5 and 160 µg/ml, 126 µg/ml 
trehalose dihydrate (6.3 µg in a volume of 50 µl, producing 6 µg of glucose) was considered a 
suitable concentration for the testing of trehalase. The combination of trehalose and trehalase 
was assessed in 0.1 M sodium maleate buffers of pH 5.5 and pH 7 containing 0.5 mg/ml BSA, 
incubated in a 40°C water bath. Aliquots were collected for assessment at different time 
points; before incubation, after 5 minutes, 30, 60 and 120 minutes of incubation at 40°C. 
There was no significant difference between the different buffers or time points and no 
incubation in the water bath seemed to be required (Figure 3). However, an incubation time of 
60 minutes was chosen since it showed the highest concentration of glucose at pH 7 (which 
0
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Figure 2. Glucose recovery in different dilutions of brain lysate. 
The amount of detected glucose is indirectly represented by the absorbance at 340 nm. 
The absorbance at 0 µg of glucose represents the background absorbance, which 
increases with the concentration of the supernatant. The absorbance (A) as a function 
of the mass of added glucose in µg (m) follows the equations: 
A = 0.08m + 0.1134 , R
2
 = 0.992 (water standard) 
A = 0.0957m + 1.0019, R
2
 =0.9649 (1:1 neat supernatant) 
A = 0.0892m + 0.5493, R
2
 = 0.9971 (1:2 diluted supernatant) 
A = 0.0907m + 0.325, R
2
 = 0.9933 (1:4 diluted supernatant) 
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was chosen because it was similar to physiological pH). Controls containing all constituents 
except the trehalase showed no increase in glucose level, thus proving that there was no 
spontaneous breakdown of trehalose. 
 
 
 
 
Different amounts of trehalose were also treated with trehalase in 20 µl supernatant diluted in 
buffer (to correspond to 40 µl of 1:2 supernatant) or buffer only, to investigate whether the 
enzyme works well in this new environment, and whether the concentration can be accurately 
measured using the glucose assay. The results resembled the standard curve in water well  
(Figure 4). 
Controls were set up to check that trehalose does not interfere with the glucose kit (e.g. gives 
false positives) and to see whether there are detectable trehalose levels in a non-treated mouse 
brain. These experiments showed no unexpected detection (results not shown). 
 
-1,000
0,000
1,000
2,000
3,000
4,000
5,000
6,000
7,000
0 30 60 90 120 150
µ
g
 o
f 
g
lu
co
se
 
incubation time (min) 
pH 5.5 trehalase
pH 7 trehalase
pH 5.5 control
pH 7 control
Figure 3. Reaction time of trehalase. 
Amount of glucose produced from 6.3 µg of trehalose as a function of the time of 
incubation at 40°C. Controls were incubated without trehalase under the same 
conditions and showed no increase in glucose concentration. 
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Trehalose assay results 
Both the endogenous glucose levels and total glucose levels (including that added through the 
trehalase conversion of trehalose) were lower in the trehalose treated mice than the controls 
(Figure 5). The mean and SEM glucose concentrations in the samples from trehalose treated 
mice (n=4) were 46.58±10.39 µg per g of brain tissue after trehalase digestion (representing 
total glucose with the addition from the digested trehalose) and 41.86±7.93 µg per g before 
digestion (representing endogenous glucose). The glucose concentrations (mean and SEM) in 
the samples from control mice (n=4) were 60.94±11.39 µg/g after trehalase digestion and 
71.58±10.25 µg/g before. There was no significant difference in the glucose concentrations 
before and after trehalase digestion in the trehalose treated group or the control group, 
significance being defined as p<0.05 using the Kruskal-Wallis one-way analysis of variance. 
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Figure 4. Trehalose digestion in water, supernatant or buffer. 
The measured glucose concentration after digestion of different amounts of trehalose 
(calculated using the standard curve in water) as a function of the expected concentration of 
glucose, added in the form of trehalose. 
The correlation coefficients (R
2
) are 0.9978, 0.9955 and 0.9998 for water, supernatant and 
buffer, respectively. 
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Histology 
There was generally more staining in the motor neurons of the trehalose treated mice (Figure 
6 A), especially in the more intense staining categories, except for intense inclusions in 
female mice (Figures 6 F and H). However, faint inclusions in male mice showed an opposite 
pattern (Figure 6 D), whereas diffuse staining in male mice and faint inclusions in female 
mice showed very similar distributions between treated and untreated animals (Figures 6 B 
and D). However, none of the differences reached significance of p<0.05 in the Kruskal-
Wallis one-way analysis of variance. 
The extracellular staining showed no apparent differences between trehalose treated and 
untreated male mice (Figure 7 B) and did not reach significance by analysis using generalized 
estimating equations (OR = 1.298, p = 0.813). The same test for the extracellular staining in 
female mice (Figure 7 A) did however show significance (OR = 6.099, p = 0.031) and there 
was an obvious trend where treated females had many sections classified as having extensive 
extracellular staining and none in the category of no extracellular staining. 
 
Figure 5. Trehalose level in the CNS of 5% trehalose treated or control female SOD1
G93A 
mice at 90 days of age. 
Scatter plot showing the glucose level in the CNS of female SOD1
G93A 
mice treated with 5% 
trehalose or female SOD1
G93A 
control mice as found by enzymatic assay. The endogenous 
glucose level is defined as the glucose concentration before digestion of trehalose into glucose, 
whereas the glucose level including trehalose is the glucose concentration after trehalase 
digestion. There is no significant difference between the concentrations before and after 
trehalase digestion in the trehalose treated group (n=4) or the control group (n=4). Significance 
was defined as p<0.05 in analysis using the Kruskal-Wallis one-way analysis of variance. 
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Figure 6. Intracellular USOD-staining in 5% trehalose treated and control SOD1
G93A 
mice at 
75 days of age 
The scatter plots show the number of USOD-positive motor neurons in the spinal cord of 5% 
trehalose treated or control SOD1
G93A 
 mice, displayed for each animal and the mean of the groups 
(n=5 female and n=4 male mice per group). The graphs show the sum of all USOD-positive motor 
neurons (A), the number of diffusely stained motor neurons (B), the number of motor neurons 
containing faint inclusions (D), the number of motor neurons containing intense inclusions (F), and 
the number of motor neurons dominated by intense USOD staining (H). To the right hand side of 
each scatter plot is a corresponding picture of the degree of USOD staining (brown), from a faint, 
diffuse staining (C), to distinct but not intense inclusions (E), intense inclusions in a small portion of 
the neuron (G), and intense USOD-staining throughout a large area of the neuron (I). Observe the 
clear difference in staining intensity between (E) and (G), and the fact that the aggregates seem to 
surround vacuolar structures to a high degree in (G) and (I). 
Seven matching sections from the lumbar region (L2 – L5) of 75 day old animals were stained with 
the primary antibody USOD, and a biotinylated secondary antibody using a peroxide reaction to 
visualise the detection of SOD1 (Kaneb, 2012). Nissl staining was used to visualise nuclei and 
somas of the cells. The scale bar indicates 200 µm and is applicable to all pictures (C, E, G, I). No 
significant differences were found between treated and control animals using the Kruskal-Wallis 
one-way analysis of variance with a significance level of p<0.05 
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Figure 7. Extracellular USOD-staining in 5% trehalose treated and control SOD1
G93A 
mice at 75 days of age 
(A-B) Scatter plots showing the number of transverse sections in the spinal cord of 5% trehalose treated or control 
female (A) and male (B) SOD1
G93A 
 mice that showed no extracellular USOD-staining (none), mild-moderate 
extracellular USOD-staining (moderate), or extensive extracellular USOD-staining (extensive), displayed for each 
animal and the mean of the groups (n=5 female and n=4 male mice per group). A total of seven equivalent 
sections from the lumbar region (L2 – L5) of each animal were included. A significant difference (p=0.031) was 
observed between treated and control females, but not between treated and control male animals (p=0.813). 
Results were analysed using generalized estimating equations, odds ratio = 6.099 for females and  
odds ratio = 1.298 for males.  
(C-D) Representation of the degree of USOD-staining (brown) in the categories mild-moderate extracellular 
staining (C) and extensive extracellular staining (D). The categories are defined by the staining intensity, density 
and area covered by the extracellular aggregates. The sections were stained with USOD as primary antibody, and 
a biotinylated secondary antibody using a peroxide reaction to visualise the detection of SOD1 (Kaneb, 2012). 
Nissl staining was used to visualise nuclei and somas of the cells. Scale bar indicates 200 µm and is applicable to 
both pictures (C) and (D).  
(E-F) Enlarged sections of pictures (C) and (D), respectively. Scale bar in (E) indicates 200 µm and also  
applies to (F). 
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DISCUSSION 
The main hypothesis of this study was that trehalose does not enter the CNS in the SOD1
G93A
 
mouse model of ALS and it is over all supported by the experiments performed. Significant 
levels of trehalose were not found in the brains of trehalose treated SOD1
G93A
 mice, which is 
in accordance with the hypothesis. The histology only showed statistically significant 
differences in one of six categories (extracellular USOD staining), and only in one gender.  
Trehalose assay 
The fact that no trehalose was detected in the samples is in direct contradiction to what 
Tanaka et al. (2004) found. They reported trehalose levels of 0.11 ± 0.02 nmol per μg of 
protein in the brain of R6/2 transgenic mice, which corresponds to about 3.77 mg of trehalose 
per gram of brain tissue (see Appendix). This is over twice the fasting blood glucose reported 
for the same animals (Tanaka et al., 2004), and 40 times the highest endogenous glucose 
concentration of the brain of SOD1
G93A 
mice as measured in this experiment. This 
concentration seems extremely high and it is questionable whether it could reside inside the 
brain without affecting its delicate chemical balance. 
Theoretically, trehalose is also unlikely to be absorbed in large quantities. Most mammals, 
including mice and humans, express intestinal trehalase (Murray et al., 2000; Kamiya et al., 
2003) and it has been shown that rats do not absorb significant amounts of trehalose without 
hydrolysing it to glucose (Dahlqvist and Thompson, 1963). In addition, no mechanism for 
trehalose uptake from the intestines has been shown. To assume that mice metabolise and 
absorb trehalase in the way that has been shown for rats seems reasonable but has not been 
proven. Possible strain differences in the metabolism or absorption of trehalose have not been 
investigated, and could theoretically exist between the SOD1
G93A
 mouse investigated in this 
study and the mouse strains showing positive results of trehalose administration, including the 
R6/2 mouse used by Tanaka et al. (2004).  
Apart from the study by Tanaka et al. (2004), there are two studies in which trehalose 
ingestion has been reported to cause significant changes in the progression of neuro-
degenerative diseases, although the trehalose level of the CNS or other tissues were not 
measured. These are the investigation of the A17-1 mouse model of oculopharyngeal 
muscular dystrophy (Davies et al., 2006) and parkin-deleted/tau overexpressing mice that 
model Parkinson’s disease (Rodríguez-Navarro et al., 2010). It is interesting to find a 
decrease in the effect of trehalose in the latter study, which also reported a significant weight 
loss in trehalose treated mice. The weight loss could be interpreted as failure to alleviate a 
clinical sign, and the effects of body mass on the disease course could possibly be discussed. 
Overall the positive results from these studies suggest that trehalose does have a positive 
effect on certain conditions, despite the fact that high concentrations might not reach the CNS. 
It is possible that small quantities have a significant effect on these mouse strains, as the 
mechanism of action has not been explained. Tanaka et al. (2004) also stated that the 
possibility that positive effects of trehalose were exerted from outside the CNS could not be 
excluded. Such mechanisms remain to be elucidated.  
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It has been suggested that the net addition in glucose intake that should follow after the 
intestinal digestion of trehalose could be responsible for certain effects (Tanaka et al., 2004; 
Kaneb, 2012). This has been investigated by administration of 2 % glucose in the drinking 
water of R6/2 mice, but this did not alleviate the Huntington-like pathology of the strain 
(Tanaka et al., 2004). It has also been shown that trehalose does not cause a significant 
increase in blood glucose in R6/2 or wild-type mice (Tanaka et al., 2004), or in the mouse 
model of Parkinson’s disease (parkin-deleted/tau overexpressing) (Rodríguez-Navarro, 2010). 
No corresponding investigations have been reported for the A17-1 mouse (Davies et al., 
2006). 
The assay procedure used to measure the trehalose concentration in small volumes of brain 
lysates was thoroughly validated to accurately detect relatively slight increases in trehalose 
concentration. The glucose assay and the trehalase used were validated for use in 40 µl of the 
standardised brain lysate diluted 1:2, i.e. 20 µl of original lysate, which was used in the final 
assay. This concentration was chosen because it showed the best fit to the standard curve 
while avoiding excessive dilution. In measuring the glucose content of such a small volume, 
there is a risk of false negative answers if the actual concentration is very small, or false 
positive answers since all answers are substantially magnified when calculated as µg per g of 
tissue. All the differences between the treated and control groups (average values as presented 
in Figure 5) are within the margin of error and, as stated previously, show no statistical 
significance. Therefore there is no question about whether large amounts of trehalose were 
present in the brain lysates. 
It has not been verified that trehalose moves freely in tissue lysates produced using this 
method, so there is a possibility that the concentration of trehalose is higher in the pellet. It is 
however believed that this would require a mechanism for “trapping” the molecule, since 
trehalose is expected to behave similarly to glucose, which moves freely in this kind of 
solution. The molecule should not be limited by the cell membrane, since this should be 
properly disrupted by the pulverisation of the frozen tissue and repeated freeze-thaw. Again 
comparing to the previous study of trehalose concentrations, a similar method was used by 
Tanaka et al. (2004) to treat the brain tissue and there is no reason to believe that the small 
differences in method should account for the very different results. 
There is a big discrepancy between the endogenous glucose content of the brain of the 
SOD1
G93A
 mice in the present study and the normal blood glucose level of mice, which is 
approximately 100 mg/dl, i.e. 1000 µg/ml (Takeda et al, 2009). Part of the reason for this 
might be the transport of glucose across the blood-brain barrier and the high glucose 
consumption of the brain. The glucose concentration of the mouse brain has been reported to 
be 10-20 % of the concentration in serum (Nilsen et al., 2011), which would give a normal 
glucose concentration in the range of 100-200 µg per gram of brain. The endogenous glucose 
concentrations as measured in the SOD1
G93A
 mice ranged from 25 to 95 µg/g, which implies 
that glucose was broken down before the assay had been carried out. This is entirely possible, 
since the tissue has been collected and processed at room temperature, and a rapid 
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consumption of glucose is expected immediately post-mortem. However, a breakdown of 
glucose is no reason for concern in this type of study, since it has been established that the 
glucose concentration is stable after the heat treatment, and no trehalose is expected to be 
degraded before the addition of trehalase. This is the only enzyme known to digest trehalose 
and has never been reported to be present in the brain of any mammal. 
Since trehalose has been shown to have positive effects in cell cultures transfected with 
G93A-mutant SOD1 (Gomes et al., 2010), it is still an interesting molecule to investigate and 
alternative ways of administration should be explored. Intramuscular or intraperitoneal 
injection seems like an obvious way of circumventing the enteric digestion of trehalose and 
would make an interesting study of the effects of trehalose in SOD1
G93A
 mice. Also, more 
studies on the absorption, distribution, metabolism and mechanism of effect of ingested 
trehalose could be required in the mouse models where it has been reported to alleviate 
disease. 
Histology 
The results of the histological study showed no significant differences between treated and 
control animals, except in the extracellular USOD staining of female mice. The fact that there 
was a bigger difference in the female animals is worth considering, since female SOD1
G93A
 
mice show less pronounced pathology than do their male counterparts at the same age (Alves 
et al., 2011). Additionally, trehalose treatment has not resulted in any alleviation of the 
disease clinically or as shown by other measurements in female SOD1
G93A
 mice, although 
treated males have shown a delayed onset of weight loss (Kaneb, 2012). Taking into 
consideration the small n-values and the great range of the number of USOD positive neurons 
between the samples, there is a possibility that the significant change displayed in 
extracellular staining could be caused by chance as opposed to trehalose treatment. 
On the other hand, some of the negative results might have reached significance in a larger 
sample size. If the results are an indication of a statistically significant effect, it is particularly 
interesting to see that the number of intensely stained neurons was generally higher in female 
mice (Figures 6 F, H and Figure 7) – both in treated and untreated mice – whereas male mice 
exhibit a more aggressive pathology (Alves et al., 2011). Since it has often been assumed that 
SOD1 positive aggregates are causing the pathology, significant results showing a higher 
degree of aggregation in females would challenge this assumption. There are already 
diverging theories about the role of protein aggregates, ranging from major cause of 
pathology to a way of reducing the toxic effects of the mutated protein (Shaw, 2005), and 
future research will hopefully reveal what significance the aggregation of protein has. The 
original assumption of protein aggregation causing ALS pathology would however further 
suggest that the differences found in the female animals of this study (both significant and 
non-significant) would be coincidental. 
In working with the histology, an important and sometimes difficult task was drawing the line 
between the categories of staining. The difference between moderate and extensive 
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extracellular staining was especially difficult to define, and this might affect the validity of 
these categories. However, the variability in the assessment was controlled by making the 
final ruling on all the sections during the same day without any interference. A combined 
score of area, intensity and size of the extracellular aggregates seemed to be the most stable 
method as there were a number of variables between the different sections. The extracellular 
staining did not appear to be background staining, since it was very specific to the ventral 
horn and generally seemed to extend from heavily stained motor neurons and structures which 
appeared to be disintegrated neurons, which implies that it might originate from these cells. 
This was also noted by Kaneb (2012). Furthermore, all sections from mice of the same gender 
were stained at the same time and in an identical fashion (Kaneb, 2012). There was another 
type of extracellular staining, which was distinctly different to the one assessed in that it 
seemed to be situated in another plane, above the histological sections. Therefore, all staining 
that could be separated by changing the focus of the microscope was excluded from the study, 
but it is possible that positive staining could have been obscured and that false negatives were 
thereby created. However, it is estimated that such a margin of error should be small, since 
not many cases occurred in the ventral horn. A larger cause of error could be the sections 
which were folded upon themselves. It did seem like both “levels” of these folded sections 
were correctly stained, so in the end many of these cases were included – unless neurons were 
piled onto each other and this made the distinction of how many cells were stained difficult. 
Another possible source of error was the fact that the samples had been contaminated by 
fungus during the sucrose cryoprotection stage. This meant that most sections contained large 
tree-like, USOD-positive structures which could have been broken down into pieces that 
could be mistaken for extracellular, and maybe intracellular, staining. However, this was 
unlikely as intermediates in this potential breakdown were not observed. 
The USOD antibody has been verified by Kerman et al. (2010) to correctly stain misfolded 
SOD1, and Kaneb (2012) has reported that it only stained motor neurons in the SOD1
G93A 
mouse. Kaneb (2012) also reported that there is no significant difference within each gender, 
between the trehalose treated and control mice in the number of surviving motor neurons, 
which in itself is an indicator of the inability of trehalose to alleviate the pathology induced by 
the SOD1
G93A
 mutation. It also verifies the method of comparing the absolute number of 
stained neurons, as opposed to calculating the ratio of existing neurons, as these should 
thereby share the same relationship. 
The conclusion of this study is that trehalose does not reach the CNS in significant levels 
when ingested by the SOD1
G93A
 mouse model of ALS and that other ways of administration 
should be investigated. 
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APPENDIX 
The level of trehalose in the brain of treated mice was 0.11 ± 0.02 nmol/μg protein according 
to Tanaka et al. (2004).  
The protein content in different areas of the rat brain is 10-13 % of fresh tissue weight, and 
the corresponding figure for the human brain varies between 9-10 % (M. Banay-Schwartz et 
al., 1992). It seems reasonable to assume that the mouse brain has a similar protein 
concentration, and for simplicity 10 % will be used for the calculation. Provided that the 
molecular weight of trehalose is 342.31 (Richards et al., 2002), the conversion to mg/g of 
brain tissue should follow:  
1 𝑛𝑚𝑜𝑙 𝑡𝑟𝑒ℎ𝑎𝑙𝑜𝑠𝑒
1 µ𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
=
342.31 𝑛𝑔 𝑡𝑟𝑒ℎ𝑎𝑙𝑜𝑠𝑒
10 µ𝑔 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒
=
34.231 𝑚𝑔 𝑡𝑟𝑒ℎ𝑎𝑙𝑜𝑠𝑒
1 𝑔 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒
 
This means that the concentration of trehalose reported in the study by Tanaka et al. (2004) 
would be: 
0.11 𝑛𝑚𝑜𝑙 𝑡𝑟𝑒ℎ𝑎𝑙𝑜𝑠𝑒
1 µ𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
=
34.231 × 0.11 𝑚𝑔 𝑡𝑟𝑒ℎ𝑎𝑙𝑜𝑠𝑒
1 𝑔 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒
= 3.76541 𝑚𝑔 𝑡𝑟𝑒ℎ𝑎𝑙𝑜𝑠𝑒 𝑝𝑒𝑟 𝑔 𝑏𝑟𝑎𝑖𝑛 𝑡𝑖𝑠𝑠𝑢𝑒 
 
